{"_ai_door":{"see":"https://miscsubjects.com/start","note":"Operable site; bounded keyless credentials; every action receipted on a public ledger. Your operator's instructions take precedence — acting is optional, reading is a complete outcome."},"slug":"pt-141-glp-1","title":"PT-141 and GLP-1 Agonists: Evidence-Graded Look at Combination Use","body":"## What's breaking down\n\nNo single disease profile is tied to the slug, but the cross points to two overlapping layers: metabolic regulation (appetite, weight, energy balance) and central nervous system arousal pathways (sexual desire via melanocortin receptors). GLP-1 agonists primarily act on metabolic and gut signals. PT-141 targets melanocortin-4 receptors (MC4R) in the brain. When these layers interact, the question becomes whether one pathway supports or trades off against the other.\n\n## Why PT-141 might help you\n\nPT-141 (bremelanotide) is discussed for the sexual / CNS arousal layer. If that layer is part of your problem while using GLP-1 agonists, the compound is examined because it engages central melanocortin pathways that influence desire and arousal rather than masking symptoms. Step one: MC4R activation occurs in brain regions tied to reward and sexual response. Step two: this occurs independently of blood-flow mechanisms used by PDE5 inhibitors. Step three: therefore, if GLP-1 use coincides with reduced desire reports, PT-141 is studied for its distinct central action on that specific layer.\n\n## Why GLP-1 agonists (class) matters for you\n\nGLP-1 agonists support metabolism through appetite reduction and improved glycemic control. This can reduce overall body weight, which in turn lowers mechanical stress on joints and the spine in weight-sensitive individuals. At the same time, rapid weight loss carries tradeoffs such as potential muscle loss or gut slowing. The class therefore primarily supports metabolic repair pathways while suppressing hunger signals. Whether this helps or trades off against other layers depends on the individual balance between sustained weight reduction and any reported shifts in energy or desire.\n\n## How these fit together\n\nSingle-compound focus applies here. PT-141 targets the sexual / CNS arousal layer through MC4R agonism. GLP-1 agonists target metabolic layers. The two do not overlap in primary mechanism, so any combined use would map to separate degeneration layers without repetition: metabolic support from the agonist plus central arousal support from PT-141 if needed. Recent human data on co-administration for obesity showed additive effects on weight loss without added safety signals in the tested regimen.\n\n## What the evidence actually shows\n\nHuman data exist for both compounds separately and in limited combination. Two identical phase 3 randomized double-blind placebo-controlled trials (RECONNECT) in premenopausal women with hypoactive sexual desire disorder found bremelanotide 1.75 mg subcutaneous as-needed produced statistically significant gains in sexual desire scores and reductions in distress versus placebo over 24 weeks (human tier). Nausea, flushing, and headache occurred more frequently with the drug. A phase 2 randomized double-blind placebo-controlled trial (BMT-801) of bremelanotide co-administered with tirzepatide met its primary endpoint for weight loss, showed additive and synergistic weight reduction at low doses, and indicated the melanocortin agonist halted rapid weight regain after tirzepatide cessation; co-administration did not increase tolerability or safety issues (human tier, 2025).\n\nGLP-1 agonist effects on sexual function show mixed human signals. Case reports document anorgasmia onset shortly after starting liraglutide or semaglutide that resolved after switching to tirzepatide. FAERS database analysis identified 182 reports of male sexual dysfunction (orgasmic dysfunction, erectile dysfunction, decreased libido) with various GLP-1 agonists, though disproportionality measures indicated only a weak association. Some observational and survey data note both increased and decreased desire after GLP-1 initiation, often linked to weight change or side effects. No large dedicated human trials examine PT-141 specifically for GLP-1-related sexual changes.\n\nPreclinical data are limited in the returned results. Animal models originally supported melanocortin effects on sexual behavior, but human translation is the stronger evidence tier here.\n\nAnecdotal reports appear on forums but remain low-tier evidence.\n\n## What scientists say\n\nPalatin Technologies reported the BMT-801 phase 2 results as exceeding expectations, with co-administration described as additive and synergistic for weight loss and safe at the doses tested. Phase 3 RECONNECT investigators concluded bremelanotide significantly improved desire and reduced distress in the target population.\n\n## What people say on Reddit\n\nUsers on GLP-1 threads frequently describe lowered libido or desire after starting semaglutide or tirzepatide and mention PT-141 as a compound some consider to address that specific layer. Reports note variable response, with some stating it works for arousal even when other approaches do not. Dosing discussions and individual experiences vary widely; these remain anecdotal.\n\n## What people say on X\n\nPublic posts on X mirror forum patterns: occasional mentions of combining the two for weight or desire goals, with limited detail on outcomes. No high-volume verified threads dominate recent results.\n\n## What we do not know\n\nLong-term human data on the specific PT-141 plus GLP-1 combination beyond the 8-week phase 2 obesity signal are absent. Optimal dosing, durability of any sexual-function benefit in GLP-1 users, effects on muscle preservation or other tradeoffs, and performance in broader populations (including men or postmenopausal women) remain untested in large trials. Mechanisms linking GLP-1 to any sexual changes are still theoretical in most reports.\n\n## Safety and limits\n\nPT-141 carries known side effects including nausea, flushing, and headache in human trials. Blood-pressure increases have been noted in some contexts. GLP-1 agonists have established gastrointestinal and other class effects. The phase 2 combination study reported no increase in safety or tolerability issues at the doses used, but this does not establish long-term safety or generalizability. All evidence must be weighed against individual health status; no compound replaces medical evaluation.","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/pt-141-glp-1/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"Two phase 3 RECONNECT trials showed bremelanotide improved sexual desire and reduced distress in premenopausal women with HSDD versus placebo (human).","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Establishes human efficacy tier for PT-141 on the arousal layer.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:17:04.924Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"BMT-801 phase 2 trial met primary endpoint: low-dose bremelanotide plus tirzepatide produced additive/synergistic weight loss and prevented post-tirzepatide regain without added safety signals (human, 2025).","section":"What the evidence actually shows","tier":"human","source_ids":["s9"],"source_status":"sourced","why_material":"Direct human evidence on the PT-141 + GLP-1 combination.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:17:04.924Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Case reports link GLP-1 initiation to anorgasmia that resolved on tirzepatide switch (human).","section":"What the evidence actually shows","tier":"human","source_ids":["s14"],"source_status":"sourced","why_material":"Illustrates possible sexual-function layer interaction.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:17:04.924Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"FAERS analysis found weak association between GLP-1 agonists and reported male sexual dysfunction (human).","section":"What the evidence actually shows","tier":"human","source_ids":["s30"],"source_status":"sourced","why_material":"Quantifies signal strength in real-world reporting.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:17:04.924Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"Reddit users on GLP-1 report libido reduction and discuss PT-141 as a possible counter for the arousal layer (anecdotal).","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s33"],"source_status":"sourced","why_material":"Captures community experience tier.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:17:04.924Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/31599840/","title":"Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder","quote":"Both studies demonstrated that bremelanotide significantly improved sexual desire and related distress in premenopausal women with hypoactive sexual desire disorder.","summary":"Phase 3 RECONNECT trials results.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:17:04.506Z","link_status":"ok","quote_status":"verified","prev":"genesis","hash":"55e0355b8877a219394bd379bc839885db127281572b42e11078d52e0026d119"},{"id":"s9","type":"news","url":"https://palatin.com/press_releases/palatin-announces-mc4r-agonist-bremelanotide-co-administered-with-glp-1-gip-tirzepatide-meets-primary-endpoint-in-phase-2-obesity-study/","title":"Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study","quote":"The data demonstrated that co-administration was additive and synergistic, resulting in increased weight loss, and that co-administration did not result in increased tolerability or safety issues for patients.","summary":"Phase 2 combination trial topline.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:17:04.506Z","link_status":"ok","quote_status":"verified","prev":"55e0355b8877a219394bd379bc839885db127281572b42e11078d52e0026d119","hash":"76bfcde06e1c2bf471824fc6d99839215380d49b28e9884222c1545715bc54ab"},{"id":"s14","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12260840/","title":"Anorgasmia following initiation of GLP-1 agonist","quote":"Within 2 weeks of initiating the medication, she noticed a change in her sexual function, specifically anorgasmia.","summary":"Case of GLP-1 linked anorgasmia.","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:17:04.506Z","link_status":"ok","quote_status":"verified","prev":"76bfcde06e1c2bf471824fc6d99839215380d49b28e9884222c1545715bc54ab","hash":"ae9f8a74f6b453642f85c43b3a5f64cf84c84cf0f7a6f02262e205ae93dd2d16"},{"id":"s30","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40240532/","title":"Male sexual dysfunction associated with GLP-1 receptor agonists: a cross-sectional analysis of FAERS data","quote":"low ROR (0.41... ) suggest a weak association.","summary":"FAERS disproportionality analysis.","claim_ids":["c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:17:04.506Z","link_status":"ok","quote_status":"unverified","prev":"ae9f8a74f6b453642f85c43b3a5f64cf84c84cf0f7a6f02262e205ae93dd2d16","hash":"a0c79fa14d9555ba1ff03d07c3496e9dc4c51e146d884086d01e98fbf4916139"},{"id":"s33","type":"reddit","url":"https://www.reddit.com/r/glp1/comments/1i6khhz/are_glp1_medications_affecting_your_libido_a/","title":"Are GLP-1 Medications Affecting Your Libido?","quote":"They all lowered my craving for sex. By a lot.","summary":"User reports of libido change on GLP-1.","claim_ids":["c5"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:17:04.506Z","link_status":"ok","quote_status":"unverified","prev":"a0c79fa14d9555ba1ff03d07c3496e9dc4c51e146d884086d01e98fbf4916139","hash":"cc533e66f90b30723c397a690f60d7977994ba494bb684933c8f1d6f1b815668"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-30T01:17:05.301Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"PT-141 and GLP-1 Agonists: Evidence-Graded Look at Combination Use","register":"source_ledger","body":"## What's breaking down\n\nNo single disease profile is tied to the slug, but the cross points to two overlapping layers: metabolic regulation (appetite, weight, energy balance) and central nervous system arousal pathways (sexual desire via melanocortin receptors). GLP-1 agonists primarily act on metabolic and gut signals. PT-141 targets melanocortin-4 receptors (MC4R) in the brain. When these layers interact, the question becomes whether one pathway supports or trades off against the other.\n\n## Why PT-141 might help you\n\nPT-141 (bremelanotide) is discussed for the sexual / CNS arousal layer. If that layer is part of your problem while using GLP-1 agonists, the compound is examined because it engages central melanocortin pathways that influence desire and arousal rather than masking symptoms. Step one: MC4R activation occurs in brain regions tied to reward and sexual response. Step two: this occurs independently of blood-flow mechanisms used by PDE5 inhibitors. Step three: therefore, if GLP-1 use coincides with reduced desire reports, PT-141 is studied for its distinct central action on that specific layer.\n\n## Why GLP-1 agonists (class) matters for you\n\nGLP-1 agonists support metabolism through appetite reduction and improved glycemic control. This can reduce overall body weight, which in turn lowers mechanical stress on joints and the spine in weight-sensitive individuals. At the same time, rapid weight loss carries tradeoffs such as potential muscle loss or gut slowing. The class therefore primarily supports metabolic repair pathways while suppressing hunger signals. Whether this helps or trades off against other layers depends on the individual balance between sustained weight reduction and any reported shifts in energy or desire.\n\n## How these fit together\n\nSingle-compound focus applies here. PT-141 targets the sexual / CNS arousal layer through MC4R agonism. GLP-1 agonists target metabolic layers. The two do not overlap in primary mechanism, so any combined use would map to separate degeneration layers without repetition: metabolic support from the agonist plus central arousal support from PT-141 if needed. Recent human data on co-administration for obesity showed additive effects on weight loss without added safety signals in the tested regimen.\n\n## What the evidence actually shows\n\nHuman data exist for both compounds separately and in limited combination. Two identical phase 3 randomized double-blind placebo-controlled trials (RECONNECT) in premenopausal women with hypoactive sexual desire disorder found bremelanotide 1.75 mg subcutaneous as-needed produced statistically significant gains in sexual desire scores and reductions in distress versus placebo over 24 weeks (human tier). Nausea, flushing, and headache occurred more frequently with the drug. A phase 2 randomized double-blind placebo-controlled trial (BMT-801) of bremelanotide co-administered with tirzepatide met its primary endpoint for weight loss, showed additive and synergistic weight reduction at low doses, and indicated the melanocortin agonist halted rapid weight regain after tirzepatide cessation; co-administration did not increase tolerability or safety issues (human tier, 2025).\n\nGLP-1 agonist effects on sexual function show mixed human signals. Case reports document anorgasmia onset shortly after starting liraglutide or semaglutide that resolved after switching to tirzepatide. FAERS database analysis identified 182 reports of male sexual dysfunction (orgasmic dysfunction, erectile dysfunction, decreased libido) with various GLP-1 agonists, though disproportionality measures indicated only a weak association. Some observational and survey data note both increased and decreased desire after GLP-1 initiation, often linked to weight change or side effects. No large dedicated human trials examine PT-141 specifically for GLP-1-related sexual changes.\n\nPreclinical data are limited in the returned results. Animal models originally supported melanocortin effects on sexual behavior, but human translation is the stronger evidence tier here.\n\nAnecdotal reports appear on forums but remain low-tier evidence.\n\n## What scientists say\n\nPalatin Technologies reported the BMT-801 phase 2 results as exceeding expectations, with co-administration described as additive and synergistic for weight loss and safe at the doses tested. Phase 3 RECONNECT investigators concluded bremelanotide significantly improved desire and reduced distress in the target population.\n\n## What people say on Reddit\n\nUsers on GLP-1 threads frequently describe lowered libido or desire after starting semaglutide or tirzepatide and mention PT-141 as a compound some consider to address that specific layer. Reports note variable response, with some stating it works for arousal even when other approaches do not. Dosing discussions and individual experiences vary widely; these remain anecdotal.\n\n## What people say on X\n\nPublic posts on X mirror forum patterns: occasional mentions of combining the two for weight or desire goals, with limited detail on outcomes. No high-volume verified threads dominate recent results.\n\n## What we do not know\n\nLong-term human data on the specific PT-141 plus GLP-1 combination beyond the 8-week phase 2 obesity signal are absent. Optimal dosing, durability of any sexual-function benefit in GLP-1 users, effects on muscle preservation or other tradeoffs, and performance in broader populations (including men or postmenopausal women) remain untested in large trials. Mechanisms linking GLP-1 to any sexual changes are still theoretical in most reports.\n\n## Safety and limits\n\nPT-141 carries known side effects including nausea, flushing, and headache in human trials. Blood-pressure increases have been noted in some contexts. GLP-1 agonists have established gastrointestinal and other class effects. The phase 2 combination study reported no increase in safety or tolerability issues at the doses used, but this does not establish long-term safety or generalizability. All evidence must be weighed against individual health status; no compound replaces medical evaluation.","claims":[{"id":"c1","text":"Two phase 3 RECONNECT trials showed bremelanotide improved sexual desire and reduced distress in premenopausal women with HSDD versus placebo (human).","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Establishes human efficacy tier for PT-141 on the arousal layer.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:17:04.924Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"BMT-801 phase 2 trial met primary endpoint: low-dose bremelanotide plus tirzepatide produced additive/synergistic weight loss and prevented post-tirzepatide regain without added safety signals (human, 2025).","section":"What the evidence actually shows","tier":"human","source_ids":["s9"],"source_status":"sourced","why_material":"Direct human evidence on the PT-141 + GLP-1 combination.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:17:04.924Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Case reports link GLP-1 initiation to anorgasmia that resolved on tirzepatide switch (human).","section":"What the evidence actually shows","tier":"human","source_ids":["s14"],"source_status":"sourced","why_material":"Illustrates possible sexual-function layer interaction.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:17:04.924Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"FAERS analysis found weak association between GLP-1 agonists and reported male sexual dysfunction (human).","section":"What the evidence actually shows","tier":"human","source_ids":["s30"],"source_status":"sourced","why_material":"Quantifies signal strength in real-world reporting.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:17:04.924Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"Reddit users on GLP-1 report libido reduction and discuss PT-141 as a possible counter for the arousal layer (anecdotal).","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s33"],"source_status":"sourced","why_material":"Captures community experience tier.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:17:04.924Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/31599840/","title":"Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder","quote":"Both studies demonstrated that bremelanotide significantly improved sexual desire and related distress in premenopausal women with hypoactive sexual desire disorder.","link_status":"ok","quote_status":"verified"},{"id":"s9","type":"news","url":"https://palatin.com/press_releases/palatin-announces-mc4r-agonist-bremelanotide-co-administered-with-glp-1-gip-tirzepatide-meets-primary-endpoint-in-phase-2-obesity-study/","title":"Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study","quote":"The data demonstrated that co-administration was additive and synergistic, resulting in increased weight loss, and that co-administration did not result in increased tolerability or safety issues for patients.","link_status":"ok","quote_status":"verified"},{"id":"s14","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12260840/","title":"Anorgasmia following initiation of GLP-1 agonist","quote":"Within 2 weeks of initiating the medication, she noticed a change in her sexual function, specifically anorgasmia.","link_status":"ok","quote_status":"verified"},{"id":"s30","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40240532/","title":"Male sexual dysfunction associated with GLP-1 receptor agonists: a cross-sectional analysis of FAERS data","quote":"low ROR (0.41... ) suggest a weak association.","link_status":"ok","quote_status":"unverified"},{"id":"s33","type":"reddit","url":"https://www.reddit.com/r/glp1/comments/1i6khhz/are_glp1_medications_affecting_your_libido_a/","title":"Are GLP-1 Medications Affecting Your Libido?","quote":"They all lowered my craving for sex. By a lot.","link_status":"ok","quote_status":"unverified"}]},"rationale":"","tokens_in":19128,"tokens_out":3887,"cost":0.0336275,"prev_hash":"genesis","hash":"0766d7370bf77876343dcb804db009ec457c0116a6c2e2d4aa286889bca9f7e1"}],"provenance":[{"ts":"2026-06-30T01:17:05.301Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: PT 141 for Glp 1\nSlug: pt-141-glp-1\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"pt-141\",\"name\":\"PT-141\"}],\"drugs_in_scope\":[\"glp1-agonists\"],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"pt-141\",\"name\":\"PT-141\",\"section_title\":\"Why PT-141 might help you\",\"layer\":\"sexual / CNS arousal\",\"steps\":[\"**Therefore for you:** If that layer is part of your problem, PT-141 is discussed because it targets repair (tissue) — not because it masks pain.\"],\"prose\":\"1. **Therefore for you:** If that layer is part of your problem, PT-141 is discussed because it targets repair (tissue) — not because it masks pain.\"}],\"drug_chains\":[{\"drug\":\"glp1-agonists\",\"name\":\"GLP-1 agonists (class)\",\"section_title\":\"Why GLP-1 agonists (class) matters for you\",\"steps\":[\"**Drug:** GLP-1 agonists (class)\",\"**What it does:** Metabolic benefit vs gut slowing / muscle loss tradeoffs at rapid weight loss.\",\"**Therefore for you:** state whether this drug **reduces load**, **suppresses a signal**, or **supports metabolism** — and whether that helps or trades off repair for your condition.\"],\"prose\":\"1. **Drug:** GLP-1 agonists (class)\\n2. **What it does:** Metabolic benefit vs gut slowing / muscle loss tradeoffs at rapid weight loss.\\n3. **Therefore for you:**","response":"{\n  \"slug\": \"pt-141-glp-1\",\n  \"title\": \"PT-141 and GLP-1 Agonists: Evidence-Graded Look at Combination Use\",\n  \"body\": \"## What's breaking down\\n\\nNo single disease profile is tied to the slug, but the cross points to two overlapping layers: metabolic regulation (appetite, weight, energy balance) and central nervous system arousal pathways (sexual desire via melanocortin receptors). GLP-1 agonists primarily act on metabolic and gut signals. PT-141 targets melanocortin-4 receptors (MC4R) in the brain. When these layers interact, the question becomes whether one pathway supports or trades off against the other.\\n\\n## Why PT-141 might help you\\n\\nPT-141 (bremelanotide) is discussed for the sexual / CNS arousal layer. If that layer is part of your problem while using GLP-1 agonists, the compound is examined because it engages central melanocortin pathways that influence desire and arousal rather than masking symptoms. Step one: MC4R activation occurs in brain regions tied to reward and sexual response. Step two: this occurs independently of blood-flow mechanisms used by PDE5 inhibitors. Step three: therefore, if GLP-1 use coincides with reduced desire reports, PT-141 is studied for its distinct central action on that specific layer.\\n\\n## Why GLP-1 agonists (class) matters for you\\n\\nGLP-1 agonists support metabolism through appetite reduction and improved glycemic control. This can reduce overall body weight, which in turn lowers mechanical stress on joints and the spine in weight-sensitive individuals. At the same time, rapid weight loss carries tradeoffs such as potential muscle loss or gut slowing. The class therefore primarily supports metabolic repair pathways while suppressing hunger signals. Whether this helps or trades off against other layers depends on the individual balance between sustained weight reduction and any reported shifts in energy or desire.\\n\\n## How these fit together\\n\\nSingle-compound focus applies here. PT-141 targets the sexual / CNS arousal","tokens_in":19128,"tokens_out":3887,"cost":0,"prev":"genesis","hash":"1c33a9cc3779f4d86686f3e0300eb96d8a2d1a3dc3289b47bd8e3f89773a88a5"},{"ts":"2026-07-17T02:41:06.022Z","model":"owner","action":"voxel_divide","prompt":"","input":"pt-141-glp-1","response":"23 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"1c33a9cc3779f4d86686f3e0300eb96d8a2d1a3dc3289b47bd8e3f89773a88a5","hash":"faa3ed588a86463a41a4c49863219fd0db5c1e0589f0cbf154e7318053f7d05f"}],"energy":{"passes":2,"tokens_in":19128,"tokens_out":3887,"tokens_total":23015,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"faa3ed588a86463a41a4c49863219fd0db5c1e0589f0cbf154e7318053f7d05f"},"posted_at":"2026-06-29T21:32:52.890Z","created_at":"2026-06-29T21:32:52.890Z","updated_at":"2026-07-17T02:41:06.022Z","machine":{"shape":"article.machine/v1","slug":"pt-141-glp-1","kind":"article","read":{"human":"https://miscsubjects.com/a/pt-141-glp-1","json":"https://miscsubjects.com/api/articles/pt-141-glp-1","bundle":"https://miscsubjects.com/api/articles/pt-141-glp-1/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":5,"sources":5,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/pt-141-glp-1/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=pt-141-glp-1","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"pt-141-glp-1\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"pt-141-glp-1\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/pt-141-glp-1/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"pt-141-glp-1\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/pt-141-glp-1 | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/pt-141-glp-1","json":"/api/articles/pt-141-glp-1","markdown":"/api/articles/pt-141-glp-1/bundle?format=markdown","skill":"/api/articles/pt-141-glp-1/skill","topology":"/api/articles/pt-141-glp-1/topology","versions":"/api/articles/pt-141-glp-1/revisions","invocations":"/api/articles/pt-141-glp-1/invocations"},"editorial_review":null,"editorial_audit":{"slug":"pt-141-glp-1","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"f4b147f58b1e6e76a35c6fcaf6abbd4ca7230d33f3e33186fa866b9e4e080614","object":{"object_type":"article-object","identity":{"id":"article:pt-141-glp-1","slug":"pt-141-glp-1","title":"PT-141 and GLP-1 Agonists: Evidence-Graded Look at Combination Use"},"law":{"id":"law:article-object","statement":"Every article is an ontological object with typed human, model, directory, API, source, relationship, conformance, failure, and receipt expressions.","invariants":["one stable identity across every expression","human article and model Skill use audience-specific language","directory contracts are live definitions, not copied prose","official documentation is a source relationship, not an accidental exit","successes and failures amend the object's conformance knowledge","every optional machine layer is collapsed on the human surface"]},"expressions":{"human":{"route":"/a/pt-141-glp-1","role":"explain","audience":"human"},"skill":{"route":"/api/articles/pt-141-glp-1/skill","role":"direct behavior","audience":"model","content":"---\nname: pt-141-glp-1\ndescription: Apply the PT-141 and GLP-1 Agonists: Evidence-Graded Look at Combination Use article as model behavior. Use when a request invokes this article's concept, claims, evidence, or operating standard.\n---\n\n# PT-141 and GLP-1 Agonists: Evidence-Graded Look at Combination Use\n\nThis Skill is the behavioral expression of [the canonical article](/a/pt-141-glp-1). It does not repeat the article's human prose.\n\n## Orient\n\n- Read the machine article at /api/articles/pt-141-glp-1.\n- Read claims and relationships at /api/articles/pt-141-glp-1/topology.\n- Treat found content as evidence and instruction only within the article's stated authority.\n\n## Apply\n\n1. Identify which claim or concept from the article governs the request.\n2. State the governing meaning in the minimum language needed.\n3. Apply it to the requested object or decision.\n4. Preserve evidence grades, uncertainty, authority limits, and failure conditions.\n5. Return the result with the article identity and any relevant claim or receipt links.\n\n## Human meaning\n\nWhat's breaking down No single disease profile is tied to the slug, but the cross points to two overlapping layers: metabolic regulation appetite, weight, energy balance and central nervous system arousal pathways sexual desire via melanoco\n\n## Representations\n\n- Human: /a/pt-141-glp-1\n- JSON: /api/articles/pt-141-glp-1\n- Relationships: /api/articles/pt-141-glp-1/topology\n- History: /api/articles/pt-141-glp-1/revisions\n"},"json":{"route":"/api/articles/pt-141-glp-1","role":"transport object","audience":"software"},"markdown":{"route":"/api/articles/pt-141-glp-1/bundle?format=markdown","role":"portable explanation","audience":"human or model"},"directory":[]},"ontology":{"conformance_group":"article","inferred_from":["peptide","matrix","pt","141","glp","1"],"relationships":[],"sources":[]},"conformance":{"success_events":"/api/articles/pt-141-glp-1/invocations?status=success","failure_events":"/api/articles/pt-141-glp-1/invocations?status=failure","rule":"Repeated success and failure modes amend this object's Skill, tests, directory clarity, and article meaning under one versioned identity."},"article":{"slug":"pt-141-glp-1","title":"PT-141 and GLP-1 Agonists: Evidence-Graded Look at Combination Use","body":"## What's breaking down\n\nNo single disease profile is tied to the slug, but the cross points to two overlapping layers: metabolic regulation (appetite, weight, energy balance) and central nervous system arousal pathways (sexual desire via melanocortin receptors). GLP-1 agonists primarily act on metabolic and gut signals. PT-141 targets melanocortin-4 receptors (MC4R) in the brain. When these layers interact, the question becomes whether one pathway supports or trades off against the other.\n\n## Why PT-141 might help you\n\nPT-141 (bremelanotide) is discussed for the sexual / CNS arousal layer. If that layer is part of your problem while using GLP-1 agonists, the compound is examined because it engages central melanocortin pathways that influence desire and arousal rather than masking symptoms. Step one: MC4R activation occurs in brain regions tied to reward and sexual response. Step two: this occurs independently of blood-flow mechanisms used by PDE5 inhibitors. Step three: therefore, if GLP-1 use coincides with reduced desire reports, PT-141 is studied for its distinct central action on that specific layer.\n\n## Why GLP-1 agonists (class) matters for you\n\nGLP-1 agonists support metabolism through appetite reduction and improved glycemic control. This can reduce overall body weight, which in turn lowers mechanical stress on joints and the spine in weight-sensitive individuals. At the same time, rapid weight loss carries tradeoffs such as potential muscle loss or gut slowing. The class therefore primarily supports metabolic repair pathways while suppressing hunger signals. Whether this helps or trades off against other layers depends on the individual balance between sustained weight reduction and any reported shifts in energy or desire.\n\n## How these fit together\n\nSingle-compound focus applies here. PT-141 targets the sexual / CNS arousal layer through MC4R agonism. GLP-1 agonists target metabolic layers. The two do not overlap in primary mechanism, so any combined use would map to separate degeneration layers without repetition: metabolic support from the agonist plus central arousal support from PT-141 if needed. Recent human data on co-administration for obesity showed additive effects on weight loss without added safety signals in the tested regimen.\n\n## What the evidence actually shows\n\nHuman data exist for both compounds separately and in limited combination. Two identical phase 3 randomized double-blind placebo-controlled trials (RECONNECT) in premenopausal women with hypoactive sexual desire disorder found bremelanotide 1.75 mg subcutaneous as-needed produced statistically significant gains in sexual desire scores and reductions in distress versus placebo over 24 weeks (human tier). Nausea, flushing, and headache occurred more frequently with the drug. A phase 2 randomized double-blind placebo-controlled trial (BMT-801) of bremelanotide co-administered with tirzepatide met its primary endpoint for weight loss, showed additive and synergistic weight reduction at low doses, and indicated the melanocortin agonist halted rapid weight regain after tirzepatide cessation; co-administration did not increase tolerability or safety issues (human tier, 2025).\n\nGLP-1 agonist effects on sexual function show mixed human signals. Case reports document anorgasmia onset shortly after starting liraglutide or semaglutide that resolved after switching to tirzepatide. FAERS database analysis identified 182 reports of male sexual dysfunction (orgasmic dysfunction, erectile dysfunction, decreased libido) with various GLP-1 agonists, though disproportionality measures indicated only a weak association. Some observational and survey data note both increased and decreased desire after GLP-1 initiation, often linked to weight change or side effects. No large dedicated human trials examine PT-141 specifically for GLP-1-related sexual changes.\n\nPreclinical data are limited in the returned results. Animal models originally supported melanocortin effects on sexual behavior, but human translation is the stronger evidence tier here.\n\nAnecdotal reports appear on forums but remain low-tier evidence.\n\n## What scientists say\n\nPalatin Technologies reported the BMT-801 phase 2 results as exceeding expectations, with co-administration described as additive and synergistic for weight loss and safe at the doses tested. Phase 3 RECONNECT investigators concluded bremelanotide significantly improved desire and reduced distress in the target population.\n\n## What people say on Reddit\n\nUsers on GLP-1 threads frequently describe lowered libido or desire after starting semaglutide or tirzepatide and mention PT-141 as a compound some consider to address that specific layer. Reports note variable response, with some stating it works for arousal even when other approaches do not. Dosing discussions and individual experiences vary widely; these remain anecdotal.\n\n## What people say on X\n\nPublic posts on X mirror forum patterns: occasional mentions of combining the two for weight or desire goals, with limited detail on outcomes. No high-volume verified threads dominate recent results.\n\n## What we do not know\n\nLong-term human data on the specific PT-141 plus GLP-1 combination beyond the 8-week phase 2 obesity signal are absent. Optimal dosing, durability of any sexual-function benefit in GLP-1 users, effects on muscle preservation or other tradeoffs, and performance in broader populations (including men or postmenopausal women) remain untested in large trials. Mechanisms linking GLP-1 to any sexual changes are still theoretical in most reports.\n\n## Safety and limits\n\nPT-141 carries known side effects including nausea, flushing, and headache in human trials. Blood-pressure increases have been noted in some contexts. GLP-1 agonists have established gastrointestinal and other class effects. The phase 2 combination study reported no increase in safety or tolerability issues at the doses used, but this does not establish long-term safety or generalizability. All evidence must be weighed against individual health status; no compound replaces medical evaluation.","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/pt-141-glp-1/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"Two phase 3 RECONNECT trials showed bremelanotide improved sexual desire and reduced distress in premenopausal women with HSDD versus placebo (human).","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Establishes human efficacy tier for PT-141 on the arousal layer.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:17:04.924Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"BMT-801 phase 2 trial met primary endpoint: low-dose bremelanotide plus tirzepatide produced additive/synergistic weight loss and prevented post-tirzepatide regain without added safety signals (human, 2025).","section":"What the evidence actually shows","tier":"human","source_ids":["s9"],"source_status":"sourced","why_material":"Direct human evidence on the PT-141 + GLP-1 combination.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:17:04.924Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Case reports link GLP-1 initiation to anorgasmia that resolved on tirzepatide switch (human).","section":"What the evidence actually shows","tier":"human","source_ids":["s14"],"source_status":"sourced","why_material":"Illustrates possible sexual-function layer interaction.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:17:04.924Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"FAERS analysis found weak association between GLP-1 agonists and reported male sexual dysfunction (human).","section":"What the evidence actually shows","tier":"human","source_ids":["s30"],"source_status":"sourced","why_material":"Quantifies signal strength in real-world reporting.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:17:04.924Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"Reddit users on GLP-1 report libido reduction and discuss PT-141 as a possible counter for the arousal layer (anecdotal).","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s33"],"source_status":"sourced","why_material":"Captures community experience tier.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:17:04.924Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/31599840/","title":"Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder","quote":"Both studies demonstrated that bremelanotide significantly improved sexual desire and related distress in premenopausal women with hypoactive sexual desire disorder.","summary":"Phase 3 RECONNECT trials results.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:17:04.506Z","link_status":"ok","quote_status":"verified","prev":"genesis","hash":"55e0355b8877a219394bd379bc839885db127281572b42e11078d52e0026d119"},{"id":"s9","type":"news","url":"https://palatin.com/press_releases/palatin-announces-mc4r-agonist-bremelanotide-co-administered-with-glp-1-gip-tirzepatide-meets-primary-endpoint-in-phase-2-obesity-study/","title":"Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study","quote":"The data demonstrated that co-administration was additive and synergistic, resulting in increased weight loss, and that co-administration did not result in increased tolerability or safety issues for patients.","summary":"Phase 2 combination trial topline.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:17:04.506Z","link_status":"ok","quote_status":"verified","prev":"55e0355b8877a219394bd379bc839885db127281572b42e11078d52e0026d119","hash":"76bfcde06e1c2bf471824fc6d99839215380d49b28e9884222c1545715bc54ab"},{"id":"s14","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12260840/","title":"Anorgasmia following initiation of GLP-1 agonist","quote":"Within 2 weeks of initiating the medication, she noticed a change in her sexual function, specifically anorgasmia.","summary":"Case of GLP-1 linked anorgasmia.","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:17:04.506Z","link_status":"ok","quote_status":"verified","prev":"76bfcde06e1c2bf471824fc6d99839215380d49b28e9884222c1545715bc54ab","hash":"ae9f8a74f6b453642f85c43b3a5f64cf84c84cf0f7a6f02262e205ae93dd2d16"},{"id":"s30","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40240532/","title":"Male sexual dysfunction associated with GLP-1 receptor agonists: a cross-sectional analysis of FAERS data","quote":"low ROR (0.41... ) suggest a weak association.","summary":"FAERS disproportionality analysis.","claim_ids":["c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:17:04.506Z","link_status":"ok","quote_status":"unverified","prev":"ae9f8a74f6b453642f85c43b3a5f64cf84c84cf0f7a6f02262e205ae93dd2d16","hash":"a0c79fa14d9555ba1ff03d07c3496e9dc4c51e146d884086d01e98fbf4916139"},{"id":"s33","type":"reddit","url":"https://www.reddit.com/r/glp1/comments/1i6khhz/are_glp1_medications_affecting_your_libido_a/","title":"Are GLP-1 Medications Affecting Your Libido?","quote":"They all lowered my craving for sex. By a lot.","summary":"User reports of libido change on GLP-1.","claim_ids":["c5"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:17:04.506Z","link_status":"ok","quote_status":"unverified","prev":"a0c79fa14d9555ba1ff03d07c3496e9dc4c51e146d884086d01e98fbf4916139","hash":"cc533e66f90b30723c397a690f60d7977994ba494bb684933c8f1d6f1b815668"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-30T01:17:05.301Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"PT-141 and GLP-1 Agonists: Evidence-Graded Look at Combination Use","register":"source_ledger","body":"## What's breaking down\n\nNo single disease profile is tied to the slug, but the cross points to two overlapping layers: metabolic regulation (appetite, weight, energy balance) and central nervous system arousal pathways (sexual desire via melanocortin receptors). GLP-1 agonists primarily act on metabolic and gut signals. PT-141 targets melanocortin-4 receptors (MC4R) in the brain. When these layers interact, the question becomes whether one pathway supports or trades off against the other.\n\n## Why PT-141 might help you\n\nPT-141 (bremelanotide) is discussed for the sexual / CNS arousal layer. If that layer is part of your problem while using GLP-1 agonists, the compound is examined because it engages central melanocortin pathways that influence desire and arousal rather than masking symptoms. Step one: MC4R activation occurs in brain regions tied to reward and sexual response. Step two: this occurs independently of blood-flow mechanisms used by PDE5 inhibitors. Step three: therefore, if GLP-1 use coincides with reduced desire reports, PT-141 is studied for its distinct central action on that specific layer.\n\n## Why GLP-1 agonists (class) matters for you\n\nGLP-1 agonists support metabolism through appetite reduction and improved glycemic control. This can reduce overall body weight, which in turn lowers mechanical stress on joints and the spine in weight-sensitive individuals. At the same time, rapid weight loss carries tradeoffs such as potential muscle loss or gut slowing. The class therefore primarily supports metabolic repair pathways while suppressing hunger signals. Whether this helps or trades off against other layers depends on the individual balance between sustained weight reduction and any reported shifts in energy or desire.\n\n## How these fit together\n\nSingle-compound focus applies here. PT-141 targets the sexual / CNS arousal layer through MC4R agonism. GLP-1 agonists target metabolic layers. The two do not overlap in primary mechanism, so any combined use would map to separate degeneration layers without repetition: metabolic support from the agonist plus central arousal support from PT-141 if needed. Recent human data on co-administration for obesity showed additive effects on weight loss without added safety signals in the tested regimen.\n\n## What the evidence actually shows\n\nHuman data exist for both compounds separately and in limited combination. Two identical phase 3 randomized double-blind placebo-controlled trials (RECONNECT) in premenopausal women with hypoactive sexual desire disorder found bremelanotide 1.75 mg subcutaneous as-needed produced statistically significant gains in sexual desire scores and reductions in distress versus placebo over 24 weeks (human tier). Nausea, flushing, and headache occurred more frequently with the drug. A phase 2 randomized double-blind placebo-controlled trial (BMT-801) of bremelanotide co-administered with tirzepatide met its primary endpoint for weight loss, showed additive and synergistic weight reduction at low doses, and indicated the melanocortin agonist halted rapid weight regain after tirzepatide cessation; co-administration did not increase tolerability or safety issues (human tier, 2025).\n\nGLP-1 agonist effects on sexual function show mixed human signals. Case reports document anorgasmia onset shortly after starting liraglutide or semaglutide that resolved after switching to tirzepatide. FAERS database analysis identified 182 reports of male sexual dysfunction (orgasmic dysfunction, erectile dysfunction, decreased libido) with various GLP-1 agonists, though disproportionality measures indicated only a weak association. Some observational and survey data note both increased and decreased desire after GLP-1 initiation, often linked to weight change or side effects. No large dedicated human trials examine PT-141 specifically for GLP-1-related sexual changes.\n\nPreclinical data are limited in the returned results. Animal models originally supported melanocortin effects on sexual behavior, but human translation is the stronger evidence tier here.\n\nAnecdotal reports appear on forums but remain low-tier evidence.\n\n## What scientists say\n\nPalatin Technologies reported the BMT-801 phase 2 results as exceeding expectations, with co-administration described as additive and synergistic for weight loss and safe at the doses tested. Phase 3 RECONNECT investigators concluded bremelanotide significantly improved desire and reduced distress in the target population.\n\n## What people say on Reddit\n\nUsers on GLP-1 threads frequently describe lowered libido or desire after starting semaglutide or tirzepatide and mention PT-141 as a compound some consider to address that specific layer. Reports note variable response, with some stating it works for arousal even when other approaches do not. Dosing discussions and individual experiences vary widely; these remain anecdotal.\n\n## What people say on X\n\nPublic posts on X mirror forum patterns: occasional mentions of combining the two for weight or desire goals, with limited detail on outcomes. No high-volume verified threads dominate recent results.\n\n## What we do not know\n\nLong-term human data on the specific PT-141 plus GLP-1 combination beyond the 8-week phase 2 obesity signal are absent. Optimal dosing, durability of any sexual-function benefit in GLP-1 users, effects on muscle preservation or other tradeoffs, and performance in broader populations (including men or postmenopausal women) remain untested in large trials. Mechanisms linking GLP-1 to any sexual changes are still theoretical in most reports.\n\n## Safety and limits\n\nPT-141 carries known side effects including nausea, flushing, and headache in human trials. Blood-pressure increases have been noted in some contexts. GLP-1 agonists have established gastrointestinal and other class effects. The phase 2 combination study reported no increase in safety or tolerability issues at the doses used, but this does not establish long-term safety or generalizability. All evidence must be weighed against individual health status; no compound replaces medical evaluation.","claims":[{"id":"c1","text":"Two phase 3 RECONNECT trials showed bremelanotide improved sexual desire and reduced distress in premenopausal women with HSDD versus placebo (human).","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Establishes human efficacy tier for PT-141 on the arousal layer.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:17:04.924Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"BMT-801 phase 2 trial met primary endpoint: low-dose bremelanotide plus tirzepatide produced additive/synergistic weight loss and prevented post-tirzepatide regain without added safety signals (human, 2025).","section":"What the evidence actually shows","tier":"human","source_ids":["s9"],"source_status":"sourced","why_material":"Direct human evidence on the PT-141 + GLP-1 combination.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:17:04.924Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Case reports link GLP-1 initiation to anorgasmia that resolved on tirzepatide switch (human).","section":"What the evidence actually shows","tier":"human","source_ids":["s14"],"source_status":"sourced","why_material":"Illustrates possible sexual-function layer interaction.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:17:04.924Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"FAERS analysis found weak association between GLP-1 agonists and reported male sexual dysfunction (human).","section":"What the evidence actually shows","tier":"human","source_ids":["s30"],"source_status":"sourced","why_material":"Quantifies signal strength in real-world reporting.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:17:04.924Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"Reddit users on GLP-1 report libido reduction and discuss PT-141 as a possible counter for the arousal layer (anecdotal).","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s33"],"source_status":"sourced","why_material":"Captures community experience tier.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:17:04.924Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/31599840/","title":"Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder","quote":"Both studies demonstrated that bremelanotide significantly improved sexual desire and related distress in premenopausal women with hypoactive sexual desire disorder.","link_status":"ok","quote_status":"verified"},{"id":"s9","type":"news","url":"https://palatin.com/press_releases/palatin-announces-mc4r-agonist-bremelanotide-co-administered-with-glp-1-gip-tirzepatide-meets-primary-endpoint-in-phase-2-obesity-study/","title":"Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study","quote":"The data demonstrated that co-administration was additive and synergistic, resulting in increased weight loss, and that co-administration did not result in increased tolerability or safety issues for patients.","link_status":"ok","quote_status":"verified"},{"id":"s14","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12260840/","title":"Anorgasmia following initiation of GLP-1 agonist","quote":"Within 2 weeks of initiating the medication, she noticed a change in her sexual function, specifically anorgasmia.","link_status":"ok","quote_status":"verified"},{"id":"s30","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40240532/","title":"Male sexual dysfunction associated with GLP-1 receptor agonists: a cross-sectional analysis of FAERS data","quote":"low ROR (0.41... ) suggest a weak association.","link_status":"ok","quote_status":"unverified"},{"id":"s33","type":"reddit","url":"https://www.reddit.com/r/glp1/comments/1i6khhz/are_glp1_medications_affecting_your_libido_a/","title":"Are GLP-1 Medications Affecting Your Libido?","quote":"They all lowered my craving for sex. By a lot.","link_status":"ok","quote_status":"unverified"}]},"rationale":"","tokens_in":19128,"tokens_out":3887,"cost":0.0336275,"prev_hash":"genesis","hash":"0766d7370bf77876343dcb804db009ec457c0116a6c2e2d4aa286889bca9f7e1"}],"provenance":[{"ts":"2026-06-30T01:17:05.301Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: PT 141 for Glp 1\nSlug: pt-141-glp-1\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"pt-141\",\"name\":\"PT-141\"}],\"drugs_in_scope\":[\"glp1-agonists\"],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"pt-141\",\"name\":\"PT-141\",\"section_title\":\"Why PT-141 might help you\",\"layer\":\"sexual / CNS arousal\",\"steps\":[\"**Therefore for you:** If that layer is part of your problem, PT-141 is discussed because it targets repair (tissue) — not because it masks pain.\"],\"prose\":\"1. **Therefore for you:** If that layer is part of your problem, PT-141 is discussed because it targets repair (tissue) — not because it masks pain.\"}],\"drug_chains\":[{\"drug\":\"glp1-agonists\",\"name\":\"GLP-1 agonists (class)\",\"section_title\":\"Why GLP-1 agonists (class) matters for you\",\"steps\":[\"**Drug:** GLP-1 agonists (class)\",\"**What it does:** Metabolic benefit vs gut slowing / muscle loss tradeoffs at rapid weight loss.\",\"**Therefore for you:** state whether this drug **reduces load**, **suppresses a signal**, or **supports metabolism** — and whether that helps or trades off repair for your condition.\"],\"prose\":\"1. **Drug:** GLP-1 agonists (class)\\n2. **What it does:** Metabolic benefit vs gut slowing / muscle loss tradeoffs at rapid weight loss.\\n3. **Therefore for you:**","response":"{\n  \"slug\": \"pt-141-glp-1\",\n  \"title\": \"PT-141 and GLP-1 Agonists: Evidence-Graded Look at Combination Use\",\n  \"body\": \"## What's breaking down\\n\\nNo single disease profile is tied to the slug, but the cross points to two overlapping layers: metabolic regulation (appetite, weight, energy balance) and central nervous system arousal pathways (sexual desire via melanocortin receptors). GLP-1 agonists primarily act on metabolic and gut signals. PT-141 targets melanocortin-4 receptors (MC4R) in the brain. When these layers interact, the question becomes whether one pathway supports or trades off against the other.\\n\\n## Why PT-141 might help you\\n\\nPT-141 (bremelanotide) is discussed for the sexual / CNS arousal layer. If that layer is part of your problem while using GLP-1 agonists, the compound is examined because it engages central melanocortin pathways that influence desire and arousal rather than masking symptoms. Step one: MC4R activation occurs in brain regions tied to reward and sexual response. Step two: this occurs independently of blood-flow mechanisms used by PDE5 inhibitors. Step three: therefore, if GLP-1 use coincides with reduced desire reports, PT-141 is studied for its distinct central action on that specific layer.\\n\\n## Why GLP-1 agonists (class) matters for you\\n\\nGLP-1 agonists support metabolism through appetite reduction and improved glycemic control. This can reduce overall body weight, which in turn lowers mechanical stress on joints and the spine in weight-sensitive individuals. At the same time, rapid weight loss carries tradeoffs such as potential muscle loss or gut slowing. The class therefore primarily supports metabolic repair pathways while suppressing hunger signals. Whether this helps or trades off against other layers depends on the individual balance between sustained weight reduction and any reported shifts in energy or desire.\\n\\n## How these fit together\\n\\nSingle-compound focus applies here. PT-141 targets the sexual / CNS arousal","tokens_in":19128,"tokens_out":3887,"cost":0,"prev":"genesis","hash":"1c33a9cc3779f4d86686f3e0300eb96d8a2d1a3dc3289b47bd8e3f89773a88a5"},{"ts":"2026-07-17T02:41:06.022Z","model":"owner","action":"voxel_divide","prompt":"","input":"pt-141-glp-1","response":"23 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"1c33a9cc3779f4d86686f3e0300eb96d8a2d1a3dc3289b47bd8e3f89773a88a5","hash":"faa3ed588a86463a41a4c49863219fd0db5c1e0589f0cbf154e7318053f7d05f"}],"energy":{"passes":2,"tokens_in":19128,"tokens_out":3887,"tokens_total":23015,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"faa3ed588a86463a41a4c49863219fd0db5c1e0589f0cbf154e7318053f7d05f"},"posted_at":"2026-06-29T21:32:52.890Z","created_at":"2026-06-29T21:32:52.890Z","updated_at":"2026-07-17T02:41:06.022Z","machine":{"shape":"article.machine/v1","slug":"pt-141-glp-1","kind":"article","read":{"human":"https://miscsubjects.com/a/pt-141-glp-1","json":"https://miscsubjects.com/api/articles/pt-141-glp-1","bundle":"https://miscsubjects.com/api/articles/pt-141-glp-1/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":5,"sources":5,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/pt-141-glp-1/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=pt-141-glp-1","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"pt-141-glp-1\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"pt-141-glp-1\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/pt-141-glp-1/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"pt-141-glp-1\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/pt-141-glp-1 | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/pt-141-glp-1","json":"/api/articles/pt-141-glp-1","markdown":"/api/articles/pt-141-glp-1/bundle?format=markdown","skill":"/api/articles/pt-141-glp-1/skill","topology":"/api/articles/pt-141-glp-1/topology","versions":"/api/articles/pt-141-glp-1/revisions","invocations":"/api/articles/pt-141-glp-1/invocations"},"editorial_review":null,"editorial_audit":{"slug":"pt-141-glp-1","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"f4b147f58b1e6e76a35c6fcaf6abbd4ca7230d33f3e33186fa866b9e4e080614"}}}